We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

74 hedge funds and large institutions have $88.5M invested in Generation Bio in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.56% less ownership

Funds ownership: 8.68%8.12% (-0.56%)

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

1% less funds holding

Funds holding: 7574 (-1)

59% less capital invested

Capital invested by funds: $217M → $88.5M (-$128M)

Holders
74
Holders Change
-1
Holders Change %
-1.33%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
18
Increased
32
Reduced
15
Closed
19
Calls
$5K
Puts
Net Calls
+$5K
Net Calls Change
-$2K
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$13.7M
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$11.4M -$922K -52,853 -7%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$8.83M -$5.37M -308,037 -37%
BG
4
Bellevue Group
Switzerland
$5.97M
BlackRock
5
BlackRock
New York
$5.23M -$323K -18,532 -6%
AG
6
Artal Group
Luxembourg
$4.64M
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.21M +$372K +21,347 +9%
Bank of America
8
Bank of America
North Carolina
$4.17M +$3.52M +202,034 +398%
Morgan Stanley
9
Morgan Stanley
New York
$3.51M +$2.83M +162,516 +323%
EC
10
EcoR1 Capital
California
$3.38M
PHS
11
PFM Health Sciences
California
$2.68M -$1.56M -89,195 -35%
Deutsche Bank
12
Deutsche Bank
Germany
$2.03M +$2.12M +121,312 +6,318%
Goldman Sachs
13
Goldman Sachs
New York
$1.91M +$818K +46,904 +68%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.78M +$115K +6,619 +7%
State Street
15
State Street
Massachusetts
$1.52M +$14.4K +824 +0.9%
UBS Group
16
UBS Group
Switzerland
$1.43M +$819K +46,979 +118%
Millennium Management
17
Millennium Management
New York
$1.24M +$1.26M +72,208 +2,354%
Renaissance Technologies
18
Renaissance Technologies
New York
$1.14M +$653K +37,460 +119%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$1.13M -$137K -7,832 -10%
Charles Schwab
20
Charles Schwab
California
$629K +$8.49K +487 +1%
Northern Trust
21
Northern Trust
Illinois
$616K +$3.89K +223 +0.6%
TD Asset Management
22
TD Asset Management
Ontario, Canada
$562K -$115K -6,591 -16%
Two Sigma Investments
23
Two Sigma Investments
New York
$523K +$553K +31,708 New
JP Morgan Chase
24
JP Morgan Chase
New York
$472K -$1.96M -112,456 -80%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$467K +$450K +25,812 +1,033%

GBIO Hedge Fund Activity: Q4 2023 in Review

74 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2023, worth a combined $88.5M — down 59% from $217M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of GBIO and 18 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 32 added.

The largest buyer was Bank of America, adding an estimated $3.52M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $13.3M sold.

  • 74 institutional investors held Generation Bio (GBIO) as of Q4 2023, down from 75 in Q3 2023.
  • Funds reported $88.5M of Generation Bio stock for Q4 2023, down 59% quarter-over-quarter.
  • 18 funds opened new Generation Bio positions in Q4 2023 and 19 closed out, a net change of -1 holder.
  • The largest Generation Bio buyer in Q4 2023 was Bank of America, an estimated $3.52M added.
  • The largest Generation Bio seller in Q4 2023 was T. Rowe Price Investment Management, an estimated $13.3M sold.

Based on aggregated 13F filings for Q4 2023.